A Study to Evaluate the Efficacy and Safety of Once-Weekly MET097 in Adults With Obesity or Overweight and T2DM

Study Summary

This study is designed to test how well once-weekly MET097 (an ultra-long-acting GLP-1 receptor agonist) works to treat adults with obesity or overweight and type 2 diabetes mellitus (T2DM) compared to placebo. MET097 or placebo will be administered to individuals via subcutaneous injection once weekly for 28 weeks. If an individual is randomly assigned to MET097 they will receive one of four different dose regimens.

Conditions

Obesity in Diabetes Type 2 Diabetes Mellitus (T2DM)

Interventions / Drugs

MET097 Injection Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment133 participants

Primary Completion—

Lead SponsorMetsera, a wholly owned subsidiary of Pfizer

Data Retrieved2026-04-11 02:55:53.189725+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.